Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
George Rennie, Angus Wilkinson, Andrew White, Marinella Ruospo, Armando Teixeira-Pinto & Giovanni Strippoli. (2019) Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis. Current Medical Research and Opinion 35:8, pages 1421-1431.
Read now
Read now
Yasutaka Takagi, Kazunori Santo, Masayo Hashimoto & Takeo Fukuchi. (2018) Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review. Clinical Ophthalmology 12, pages 1837-1844.
Read now
Read now
Albert Alm. (2014) Latanoprost in the treatment of glaucoma. Clinical Ophthalmology 8, pages 1967-1985.
Read now
Read now
E Randy Craven & Sultan A Alzuhairy. (2014) Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications. Expert Review of Ophthalmology 9:3, pages 159-173.
Read now
Read now
Stefan Pfennigsdorf, Osman Ramez, Gerrit von Kistowski, Birgit Mäder, Peter Eschstruth, Michael Froböse, Ulrich Thelen, Christoph Spraul, Dietmar Schnober, Hazel Cooper & Thomas Laube. (2012) Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 6, pages 739-746.
Read now
Read now
Antoine Lafuma, John F Salmon, Julien Robert & Gilles Berdeaux. (2011) Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database. Clinical Ophthalmology 5, pages 361-367.
Read now
Read now
F. Aptel & P. Denis. (2011) Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma. Current Medical Research and Opinion 27:10, pages 1949-1958.
Read now
Read now
Anne J Lee & Peter McCluskey. (2010) Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology 4, pages 741-764.
Read now
Read now
E Randy Craven, Ching-Chi Liu, Amy Batoosingh, Rhett M Schiffman & Scott M Whitcup. (2010) A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. Clinical Ophthalmology 4, pages 1433-1440.
Read now
Read now
Jordana K Schmier, Edmund C Lau & David W Covert. (2010) Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clinical Ophthalmology 4, pages 1137-1143.
Read now
Read now
Anders Bergström, Frédérique Maurel, Claude Le Pen, Emilie Lamure, Michael Kent, Isabelle Bardoulat & Gilles Berdeaux. (2009) Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden. Clinical Ophthalmology 3, pages 471-481.
Read now
Read now
Oghenowede Eyawo, Jean Nachega, Pierre Lefebvre, David Meyer, Beth Rachlis, Chia-Wen Lee, Steven Kelly & Edward Mills. (2009) Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clinical Ophthalmology 3, pages 447-456.
Read now
Read now
C.-W. Lee, F. Buckley, S. Costello & S. Kelly. (2008) A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma. Current Medical Research and Opinion 24:8, pages 2265-2270.
Read now
Read now
Articles from other publishers (49)
V. N. Fedorov, V. P. Vdovichenko, M. K. Korsakov, V. V. Strakhov, A. A. Popova, A. I. Khokhlov & S. S. Suleymanov. (2023) Pharmacotherapy of glaucoma in terms of evidence-based medicine. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice:3, pages 44-54.
Crossref
Crossref
Katarzyna Asendrych-Wicik, Jakub Zarczuk, Katarzyna Walaszek, Tomasz Ciach & Magdalena Markowicz-Piasecka. (2023) Trends in development and quality assessment of pharmaceutical formulations - F2α analogues in the glaucoma treatment. European Journal of Pharmaceutical Sciences 180, pages 106315.
Crossref
Crossref
Lin Zhou, Wenyi Zhan & Xin Wei. (2022) Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Frontiers in Pharmacology 13.
Crossref
Crossref
Mohammadsadegh Hamzehnejadi, Marziye Ranjbar Tavakoli, Fatemeh Homayouni, Zahra Jahani, Masoud Rezaei, Mohammad Amin Langarizadeh & Hamid Forootanfar. (2022) Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. Sexual Medicine Reviews 10:4, pages 764-781.
Crossref
Crossref
María I. Canut, Olaya Villa, Bachar Kudsieh, Heidi Mattlin, Isabel Banchs, Juan R. González, Lluís Armengol & Ricardo P. Casaroli-Marano. (2021) MLIP genotype as a predictor of pharmacological response in primary open-angle glaucoma and ocular hypertension. Scientific Reports 11:1.
Crossref
Crossref
Kang-Jung Lo, Yu-Chieh Ko, De-Kuang Hwang & Catherine Jui-Ling Liu. (2020) The influence of topical non-steroidal anti-inflammatory drugs on the intraocular pressure lowering effect of topical prostaglandin analogues—A systemic review and meta-analysis. PLOS ONE 15:9, pages e0239233.
Crossref
Crossref
Alok Dixit, Atul Ashish & Reena Sharma. (2020) A comparative study on efficacy of fixed combination timolol/brinzolamide versus travoprost monotherapy in drug-naïve open-angle glaucoma patients. Therapeutic Advances in Ophthalmology 12, pages 251584142090966.
Crossref
Crossref
Wenquan Tang, Feng Zhang, Ke Liu & Xuanchu Duan. (2019) Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients. Medicine 98:30, pages e16597.
Crossref
Crossref
V. P. Erichev, I. V. Kozlova & J. V. Kosova. (2019) Frequency and type of macular edema after cataract surgery in patients with glaucoma. Vestnik oftal'mologii 135:5, pages 241.
Crossref
Crossref
Fei Li, Wenbin Huang & Xiulan Zhang. (2018) Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmologica 96:3, pages e277-e284.
Crossref
Crossref
Wissam Georges El Hajj Moussa, Rebecca Georges Farhat, Joseph Claud Nehme, Marwan Antoun Sahyoun, Alexandre Raymond Schakal, Alexandre Edmond Jalkh, Mariana Pierre Abi Karam & Georges Georges Azar. (2018) Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients. Journal of Ophthalmology 2018, pages 1-7.
Crossref
Crossref
Caner KARA, Emine Malkoç ŞEN, Kadriye Ufuk ELGİN, Kurtuluş SERDAR & Pelin YILMAZBAŞ. (2016) Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?. International Ophthalmology 37:3, pages 619-626.
Crossref
Crossref
Yury S Astakhov & Pavel A Nechiporenko. (2017) Prostaglandin analogues: past, present, and future. Ophthalmology Reports 10:1, pages 40-52.
Crossref
Crossref
Kazuhide Kawase, Jason L. Vittitow, Robert N. Weinreb, Makoto Araie, Shigeru Hoshiai, Setsuko Hashida, Miki Iwasaki, Kiyoshi Kano, Kazuhide Kawase, Takuji Kato, Yasuaki Kuwayama, Tomoyuki Muramatsu, Masatada Mitsuhashi, Sakae Matsuzaki, Toru Nakajima, Isao Sato & Yuzuru Yoshimura. (2016) Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Advances in Therapy 33:9, pages 1612-1627.
Crossref
Crossref
A. Chabi, C. Baranak, R. Lupinacci & W. J. Herring. (2016) Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. International Journal of Clinical Practice 70:7, pages 577-586.
Crossref
Crossref
Mitsuhiro Imasawa, Joji Tanabe, Fumiko Kashiwagi & Kenji Kashiwagi. (2016) Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost. The Open Ophthalmology Journal 10:1, pages 94-102.
Crossref
Crossref
Christophe Baudouin, Keith Barton, Michele Cucherat & Carlo Traverso. (2015) The Measurement of Bulbar Hyperemia: Challenges and Pitfalls. European Journal of Ophthalmology 25:4, pages 273-279.
Crossref
Crossref
Liang Lin, Ying Jiao Zhao, Paul T.K. Chew, Chelvin C. A. Sng, Hon-Tym Wong, Leonard W. Yip, Tuck Seng Wu, Dianne Bautista, Monica Teng, Ai Leng Khoo & Boon Peng Lim. (2014) Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy 48:12, pages 1585-1593.
Crossref
Crossref
Colin I. Clement, Shibal Bhartiya & Tarek Shaarawy. (2014) New perspectives on target intraocular pressure. Survey of Ophthalmology 59:6, pages 615-626.
Crossref
Crossref
Nelson S. WinklerMichael P. Fautsch. (2014) Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways. Journal of Ocular Pharmacology and Therapeutics 30:2-3, pages 102-109.
Crossref
Crossref
Lars Wagenfeld, Hendrik Schwarzer, Gernot Roessler, Maren Klemm, Christos Skevas, Gisbert Richard & Oliver Zeitz. (2014) Dose-Response-Relationship between Number of Laser Burns and IOP Reduction in Cyclophotocoagulation: An Animal Study. BioMed Research International 2014, pages 1-5.
Crossref
Crossref
Paul N. Schacknow & John R. Samples. 2014. Clinical Glaucoma Care. Clinical Glaucoma Care
417
477
.
Douglas G Day, Thomas R Walters, Gail F Schwartz, Thomas K Mundorf, Charlie Liu, Rhett M Schiffman & Marina Bejanian. (2013) Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. British Journal of Ophthalmology 97:8, pages 989-993.
Crossref
Crossref
Iwona Dams, Jaromir Wasyluk, Marek Prost & Andrzej Kutner. (2013) Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies. Prostaglandins & Other Lipid Mediators 104-105, pages 109-121.
Crossref
Crossref
Tianjing Li & Kay Dickersin. (2013) Citation of Previous Meta-analyses on the Same Topic. Ophthalmology 120:6, pages 1113-1119.
Crossref
Crossref
Iwona Dams, Michał Chodyński, Małgorzata Krupa, Anita Pietraszek, Marta Zezula, Piotr Cmoch, Monika Kosińska & Andrzej Kutner. (2013)
A Novel Convergent Synthesis of the Antiglaucoma PGF
2α
Analogue Bimatoprost
. Chirality 25:3, pages 170-179.
Crossref
Crossref
Michelle Orme, Sarah Collins & Jane Loftus. (2012) Long-term Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension in the UK. Journal of Glaucoma 21:7, pages 433-449.
Crossref
Crossref
Sherratt Amanda & Needham Yvonne. (2012) Clinical update — pharmacological issues in ophthalmology. International Journal of Ophthalmic Practice 3:1, pages 43-47.
Crossref
Crossref
Helen A. Dakin, Nicky J. Welton, A.E. Ades, Sarah Collins, Michelle Orme & Steven Kelly. (2011) Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open‐angle glaucoma and ocular hypertension. Statistics in Medicine 30:20, pages 2511-2535.
Crossref
Crossref
Chris G. Pirie, Louise S. Maranda & Stefano Pizzirani. (2011) Effect of topical 0.03% flurbiprofen and 0.005% latanoprost, alone and in combination, on normal canine eyes. Veterinary Ophthalmology 14:2, pages 71-79.
Crossref
Crossref
Jianbing Ma, Weiru Liu & Anthony Hunter. (2011) Modeling and reasoning with qualitative comparative clinical knowledge. International Journal of Intelligent Systems 26:1, pages 25-46.
Crossref
Crossref
Malik Y. KahookDavid A. Ammar. (2010)
In Vitro
Toxicity of Topical Ocular Prostaglandin Analogs and Preservatives on Corneal Epithelial Cells
. Journal of Ocular Pharmacology and Therapeutics 26:3, pages 259-263.
Crossref
Crossref
L. Jay Katz, John S. Cohen, Amy L. Batoosingh, Carlos Felix, Vincent Shu & Rhett M. Schiffman. (2010) Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension. American Journal of Ophthalmology 149:4, pages 661-671.e1.
Crossref
Crossref
Sei Yamazaki, Mami Nanno, Tairo Kimura, Hirotaka Suzumura & Keiji Yoshikawa. (2010) Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Japanese Journal of Ophthalmology 54:1, pages 7-14.
Crossref
Crossref
Paul N. Schacknow & John R. Samples. 2010. The Glaucoma Book. The Glaucoma Book
583
628
.
Louis R. Pasquale. 2010. The Glaucoma Book. The Glaucoma Book
23
34
.
Monique P. Curran. (2009) Bimatoprost. Drugs & Aging 26:12, pages 1049-1071.
Crossref
Crossref
Anthea Worley & Karen Grimmer-Somers. (2009) Should we be worried about glaucoma? Why the prevalence of glaucoma is variably reported. Primary Health Care Research & Development 10:04, pages 343.
Crossref
Crossref
Renato De Natale, Antoine Lafuma & Gilles Berdeaux. (2009) The Authorsʼ Reply. Clinical Drug Investigation 29:8, pages 558.
Crossref
Crossref
Jin-Wei Cheng, Gui-Lin Xi, Rui-Li Wei, Ji-Ping Cai & You Li. (2009) Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis. Current Therapeutic Research 70:4, pages 335-350.
Crossref
Crossref
Renato De Natale, Antoine Lafuma & Gilles Berdeaux. (2009) Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma. Clinical Drug Investigation 29:2, pages 111-120.
Crossref
Crossref
Wallace L.M. Alward. (2009) How I Choose a Prostaglandin Analogue. American Journal of Ophthalmology 147:1, pages 1-2.
Crossref
Crossref
Tariq Alasbali, Michael Smith, Noa Geffen, Graham E. Trope, John G. Flanagan, Yaping Jin & Yvonne M. Buys. (2009) Discrepancy between Results and Abstract Conclusions in Industry- vs Nonindustry-funded Studies Comparing Topical Prostaglandins. American Journal of Ophthalmology 147:1, pages 33-38.e2.
Crossref
Crossref
Mauricio D Paolera, Niro Kasahara, Cristiano C Umbelino & John G Walt. (2008) Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study. BMC Ophthalmology 8:1.
Crossref
Crossref
Gerald W. Bean & Carl B. Camras. (2008) Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences. Survey of Ophthalmology 53:6, pages S69-S84.
Crossref
Crossref
Jin-Wei Cheng & Rui-Li Wei. (2008) Meta-Analysis of 13 Randomized Controlled Trials Comparing Bimatoprost with Latanoprost in Patients with Elevated Intraocular Pressure. Clinical Therapeutics 30:4, pages 622-632.
Crossref
Crossref
Stéphanie Payet, Philippe Denis, Gilles Berdeaux & Robert Launois. (2008) Assessment of the Cost Effectiveness of Travoprost versus Latanoprost as Single Agents for Treatment of Glaucoma in France. Clinical Drug Investigation 28:3, pages 183-198.
Crossref
Crossref
P. Denis, C. Le Pen, D. Umuhire & G. Berdeaux. (2018) Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model. European Journal of Ophthalmology 18:1, pages 44-51.
Crossref
Crossref
Robert M. Burk. 2008.
293
309
.